Pre-made Fresolimumab benchmark antibody ( Whole mAb, anti-TGFB/TGFB1 therapeutic antibody, Anti-CED/DPD1/IBDIMDE/LAP Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Fresolimumab biosimilar, Whole mAb, Anti-TGFB/TGFB1 Antibody: Anti-CED/DPD1/IBDIMDE/LAP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Fresolimumab (GC1008) is a human monoclonal antibody and an immunomodulator. It is intended for the treatment of idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis, and cancer (kidney cancer and melanoma).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-223-1mg	1mg	3090	30%	2163

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Fresolimumab biosimilar, Whole mAb, Anti-TGFB/TGFB1 Antibody: Anti-CED/DPD1/IBDIMDE/LAP therapeutic antibody
INN Name	Fresolimumab
Target	TGFB1
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	3eo0:DC:BA/4kxz:JI:HL:NM:QP/4kv5:EF:GK:HL:JI/3eo1:BA:ED:KJ:HG
95-98% SI Structure	None
Year Proposed	2009
Year Recommended	2010
Companies	Cambridge Antibody Technology;Baylor College of Medicine;Genzyme Corporation;Sanofi Genzyme
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Fibrosis;Malignant melanoma;Pulmonary fibrosis;Renal cancer;Focal segmental glomerulosclerosis;Osteogenesis imperfecta
Development Tech	CAT Phage Display